<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">The following definitions were used to assess the outcomes: 
 <list list-type="order">
  <list-item>
   <p id="Par33">BOS was defined according to the International Society for Heart &amp; Lung Transplantation (ISHLT) algorithm based on forced expiratory volume in 1 s (FEV-1) values [
    <xref ref-type="bibr" rid="CR8">8</xref>].
   </p>
  </list-item>
  <list-item>
   <p id="Par34">BOS-worsening was defined as a worsening in the previously defined stage of BOS.</p>
  </list-item>
  <list-item>
   <p id="Par35">AR was defined on the basis of a transbronchial biopsy that demonstrated at least a Grade A1 of acute rejection as defined by the ISHLT for cellular rejection. In patients in whom a biopsy could not be performed, acute rejection was defined by deterioration in lung function with no other identifiable aetiology and that positively responded to a high-dose corticosteroid therapy.</p>
  </list-item>
  <list-item>
   <p id="Par36">FEV-1 delta was defined as 6-month-FEV-1 – last FEV-1 before inclusion.</p>
  </list-item>
 </list>
</p>
